Le contenu

The Assises des Biothérapies et de la bioproduction en Bourgogne-Franche-Comté: united for a regional ambition!

13 March 2024 L'agence, Innovation / Recherche, Filières Santé Share :

The Biotherapies and Bioproduction Conference is being held today, March 13, 2024, at the regional council of Burgundy-Franche-Comté, in Dijon. This event will be followed by a second one, on June 19, in Besançon. These two meetings provide a unique platform for discussion and exchanges to define an ambitious regional roadmap for the sector.

Stakeholders Are Present

More than a hundred participants, including researchers, clinicians, industrialists, and support structures, have responded to the Region’s invitation. Their goal: to share their perspectives and experiences, discuss challenges in the field of biotherapies and bioproduction, and contribute to the collective reflection. The expected result: a future strategic roadmap to position the region on the map of national and international hubs.

Biotherapies are medicines derived from living organisms, such as vaccines, antibodies, and other innovative cell therapies. They simply represent the future of medicine. Bioproduction is the way these biomedicines are produced.

The event, introduced by Franck ROBINE, prefect of the Burgundy-Franche-Comté region and the Côte-d’Or, and Marie-Guite DUFAY, president of the Burgundy-Franche-Comté Region, features high-level conferences, a round table, and interactive workshops, with interventions from: Anne Jouvenceau, coordinator of the Biotherapy Bioproduction in Innovative Therapies acceleration strategy, Health Innovation Agency, Nicolas SORET, Vice-President of the Region in charge of the economy, Laetitia MARTINEZ, Vice-President of the Region in charge of research, Nicolas PARIS, CEO of Gilson and CEO of BioForward Wisconsin cluster, Philippe GENNE CEO of Oncodesign Precision Medicine, Philippe DULIEU CEO of RD Biotech, Laurent LAFFERRERE General Manager of FranceBiolead, Franck MOUTHON president of France Biotech, and Clémentine GAMONET, from the innovation pole in biotherapies of the French Blood Establishment.

The Burgundy-Franche-Comté Region Bets on the Future of Medicine

Biotherapies and bioproduction offer innovative solutions to save lives and improve patient health. The biotherapy market is growing by 9% per year according to the Strategic Council for Health Industries (CSIS) and will represent 320 billion euros by 2025.

Burgundy-Franche-Comté, with its scientific and industrial heritage, is positioned to play a leading role in this therapeutic and economic revolution. Indeed, with the presence of pharmaceutical leaders, a fabric of innovative SMEs, high-performing research institutions, and technology transfer actors, Burgundy-Franche-Comté has a fertile ground to develop the medicine of the future. The regional Health sector today represents nearly 500 establishments and 13,000 employees.

In a constantly transforming field, the challenges are significant. International competition is tough despite strong state mobilization with the France 2030 program. The Burgundy-Franche-Comté Region more than ever needs a strong collective to structure a regional sector, create jobs and added value in its territory, and participate in the development of the biomedicines of tomorrow.

The Biotherapies and Bioproduction Conference is a crucial step in building a strong and competitive regional sector. We are convinced that this event will contribute to strengthening our position on the national and international stage,” says Marie-Guite DUFAY, President of the Burgundy-Franche-Comté Region.

For his part, Franck ROBINE, Prefect of the Burgundy-Franche-Comté region, prefect of the Côte-d’Or, emphasizes that the national objective is to make France the first innovative and sovereign European nation in health. For this, the health component of France 2030 is endowed with 7.5 billion euros and is accompanied by strategic and sectoral plans. The Region’s initiative is particularly in line with the acceleration strategy “biotherapies, bioproductions,” at the heart of the health component of France 2030. Burgundy-Franche-Comté holds undeniable assets in this area that are important to develop to contribute to this national sector, especially the know-how and highly trained workforce, assets that are rooted in the region’s industrial tradition. “